

BIOSPECIFICS TECHNOLOGIES CORP  
Form 8-K  
December 22, 2014

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 22, 2014**

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34236**  
(Commission  
File Number)

**11-3054851**  
(IRS Employer  
Identification No.)

**35 Wilbur Street**  
**Lynbrook, NY**  
(Address of principal executive offices)

**11563**  
(Zip Code)

Registrant's telephone number, including area code: **516.593.7000**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Introductory Comment

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

## Item 8.01. Other Events

On December 22, 2014, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of XIAPEX® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

## Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
-----------------------	---------------------------

<b><u>No.</u></b>	<b><u>Description</u></b>
-------------------	---------------------------

<u>99.1</u>	<u>Press Release of the Company dated December 22, 2014</u>
-------------	---

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 22, 2014

**BioSpecifics Technologies Corp.**

By: /s/ Thomas L. Wegman

Name: Thomas L. Wegman

Title: President

---

**EXHIBIT INDEX**

**Exhibit    Description**

**No.**

99.1    Press Release of the Company dated December 22, 2014

---